席宏莲, 张雯静, 郑婷, 王满侠. 单克隆抗体治疗视神经脊髓炎谱系疾病的研究进展[J]. 解放军医学院学报, 2023, 44(5): 569-574. DOI: 10.3969/j.issn.2095-5227.2023.05.020
引用本文: 席宏莲, 张雯静, 郑婷, 王满侠. 单克隆抗体治疗视神经脊髓炎谱系疾病的研究进展[J]. 解放军医学院学报, 2023, 44(5): 569-574. DOI: 10.3969/j.issn.2095-5227.2023.05.020
XI Honglian, ZHANG Wenjing, ZHENG Ting, WANG Manxia. Research advances in treatment of neuromyelitis optic spectrum disorder with monoclonal antibodies[J]. ACADEMIC JOURNAL OF CHINESE PLA MEDICAL SCHOOL, 2023, 44(5): 569-574. DOI: 10.3969/j.issn.2095-5227.2023.05.020
Citation: XI Honglian, ZHANG Wenjing, ZHENG Ting, WANG Manxia. Research advances in treatment of neuromyelitis optic spectrum disorder with monoclonal antibodies[J]. ACADEMIC JOURNAL OF CHINESE PLA MEDICAL SCHOOL, 2023, 44(5): 569-574. DOI: 10.3969/j.issn.2095-5227.2023.05.020

单克隆抗体治疗视神经脊髓炎谱系疾病的研究进展

Research advances in treatment of neuromyelitis optic spectrum disorder with monoclonal antibodies

  • 摘要: 视神经脊髓炎谱系疾病(neuromyelitis optic spectrum disorder,NMOSD)是一种罕见的中枢神经系统自身免疫性炎性脱髓鞘疾病,临床上多以严重的视神经炎和纵向延伸的长节段横贯性脊髓炎为主,复发率和致残率高。目前无特效药物预防其复发,近几年单克隆抗体治疗NMOSD已取得重大突破。本文基于白细胞介素-6受体、B淋巴细胞、末端补体等,针对不同免疫靶点治疗NMOSD的单克隆抗体以及AQP4-IgG阴性患者潜在的治疗靶点进行综述。

     

    Abstract: Neuromyelitis optic spectrum disorder (NMOSD) is an inflammatory, demyelinating syndrome of the central nervous system that is characterized by severe attacks of optic neuritis and myelitis. Most patients follow a course of early incremental disability due to frequent and severe relapses. And there are no effective drugs to avoid its recurrence. Monoclonal antibodies have made remarkable breakthrough in the treatment of NMOSD. Recent studies have provided effective evidence to support the efficacy and safety of monoclonal antibodies in the treatment of NMOSD. This paper reviews the research progress of targeted drugs to interleukin-6 receptor, B cell, Complement 5, and potential treatment strategies in AQP4-IgG-seronegative NMOSD.

     

/

返回文章
返回